(Q48336812)

10 February 2018

title

Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level (English)

1 reference

10 February 2018

1 reference

3

1 reference

10 February 2018

author name string

Dan Leibovici

1

1 reference

10 February 2018

Philippe E Spiess

2

1 reference

10 February 2018

Shi-Ming Tu

4

1 reference

10 February 2018

Curtis A Pettaway

5

1 reference

10 February 2018

Kate Hitzhusen

6

1 reference

10 February 2018

Randall E Millikan

7

1 reference

10 February 2018

Louis L Pisters

8

1 reference

10 February 2018

language of work or name

English

0 references

publication date

1 January 2007

1 reference

10 February 2018

published in

Cancer

1 reference

10 February 2018

volume

109

1 reference

10 February 2018

issue

2

1 reference

10 February 2018

page(s)

198-204

1 reference

10 February 2018

Natural history of progression after PSA elevation following radical prostatectomy

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Prostatic Specific Antigen Related to Clinical Status 1 to 14 Years after Radical Retropubic Prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Metastatic prostate cancer with normal level of serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Prostate cancer with a normal PSA: small cell carcinoma of the prostate--a rare entity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Can Prostate-Specific Antigen Levels Predict Bone Scan Evidence of Metastases in Newly Diagnosed Prostate Cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Tibia metastasis without prostate specific antigen (PSA) increase following radical vesiculo-prostatectomy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Low PSA metastatic androgen- independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Stem-cell origin of metastasis and heterogeneity in solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Progression from adenocarcinoma to small cell carcinoma of the prostate with normalization of prostate-specific antigen (PSA) levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22372

7 January 2021

Identifiers

DOI

10.1002/CNCR.22372

1 reference

10 February 2018

1 reference

10 February 2018